Elevation Oncology Inc (ELEV)

Apr 25, 2025, 1:00 PM EDT - 1 day ago

Elevation Oncology Presents Preclinical Proof-of-Concept Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025

Mar 25, 2025, 4:30 PM EDT - 4 weeks ago

Elevation Oncology to Present Preclinical Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025

Mar 20, 2025, 11:46 AM EDT - 5 weeks ago

Elevation Oncology Stops Gastric Cancer Study, Slashes Staff By 70%

Mar 20, 2025, 8:00 AM EDT - 5 weeks ago

Elevation Oncology to Discontinue Development of EO-3021; Advancing EO-1022, While Evaluating Strategic Options

Mar 6, 2025, 4:30 PM EST - 7 weeks ago

Elevation Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Achievements

Feb 25, 2025, 7:30 AM EST - 2 months ago

Elevation Oncology to Participate in Upcoming Investor Conferences

Jan 13, 2025, 7:30 AM EST - 3 months ago

Elevation Oncology Provides Updates on Differentiated ADC Programs and Upcoming Milestones

Dec 12, 2024, 7:30 AM EST - 4 months ago

Elevation Oncology Expands Pipeline with Nomination of EO-1022, a HER3 ADC for the Treatment of HER3-expressing Solid Tumors

Dec 12, 2024, 7:30 AM EST - 4 months ago

Elevation Oncology Licenses ADC Technology from Synaffix to Drive Pipeline Expansion

Dec 5, 2024, 7:30 AM EST - 5 months ago

Elevation Oncology Presents Preclinical Proof-of-Concept Data Supporting Combination Potential of EO-3021 with VEGFR2 or PD-1 Inhibitors at ESMO Immuno-Oncology Annual Congress 2024

Nov 26, 2024, 7:30 AM EST - 5 months ago

Elevation Oncology to Present at the Piper Sandler 36th Annual Healthcare Conference

Nov 6, 2024, 7:30 AM EST - 6 months ago

Elevation Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Achievements

Oct 9, 2024, 12:02 PM EDT - 7 months ago

Empery Asset Management's Strategic Acquisition in Elevation Oncology

Sep 23, 2024, 7:30 AM EDT - 7 months ago

Elevation Oncology Receives Fast Track Designation from the FDA for EO-3021 for the Treatment of Adult Patients with Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Expressing Claudin 18.2

Sep 3, 2024, 7:30 AM EDT - 8 months ago

Elevation Oncology to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 9, 2024, 1:45 PM EDT - 9 months ago

Undercovered Dozen: Elevation Oncology, Ivanhoe Mines, Union Pacific, Golub Capital +

UNP

Aug 6, 2024, 12:36 PM EDT - 9 months ago

Why Is Penny Stock Elevation Oncology Trading Lower On Tuesday?

Aug 6, 2024, 10:43 AM EDT - 9 months ago

Elevation Oncology: Proving That No One Knows How To Interpret Early-Stage Clinical Results

Aug 6, 2024, 7:10 AM EDT - 9 months ago

Elevation Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Achievements

Aug 6, 2024, 7:00 AM EDT - 9 months ago

Elevation Oncology Announces Promising Initial Data from Phase 1 Clinical Trial Evaluating EO-3021 in Patients with Advanced Unresectable or Metastatic Solid Tumors Likely to Express Claudin 18.2

Jun 27, 2024, 7:30 AM EDT - 10 months ago

Elevation Oncology Announces Planned Combination Strategy for EO-3021 in Patients with Gastric or Gastroesophageal Junction Cancer

May 7, 2024, 7:30 AM EDT - 1 year ago

Elevation Oncology to Present at the Citizens JMP Life Sciences Conference

May 3, 2024, 1:16 PM EDT - 1 year ago

Elevation Oncology: Mid-2024 EO-3021 Data Could Get Ball Rolling

May 2, 2024, 7:30 AM EDT - 1 year ago

Elevation Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Achievements

Apr 22, 2024, 11:00 AM EDT - 1 year ago

Elevation Oncology: Continuing To Seek Footing As It Climbs (Rating Upgrade)

Apr 8, 2024, 4:30 PM EDT - 1 year ago

Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024

Mar 6, 2024, 7:30 AM EST - 1 year ago

Elevation Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Achievements

Mar 5, 2024, 4:50 PM EST - 1 year ago

Elevation Oncology to Present Preclinical Proof-of-Concept Data for HER3-ADC Program at the American Association for Cancer Research (AACR) Annual Meeting 2024

Mar 4, 2024, 7:30 AM EST - 1 year ago

Elevation Oncology Appoints Experienced Clinical Development Leaders Julie Cherrington, Ph.D. and Alan Sandler, M.D.

Feb 22, 2024, 7:30 AM EST - 1 year ago

Elevation Oncology Expands Ongoing Phase 1 Clinical Trial of EO-3021 Globally, Dosing First Patient in Japan

Jan 22, 2024, 7:30 AM EST - 1 year ago

Elevation Oncology Announces Appointment of Darcy Mootz, Ph.D., to its Board of Directors

Jan 5, 2024, 7:30 AM EST - 1 year ago

Elevation Oncology Announces Program Updates and Upcoming 2024 Milestones

Nov 22, 2023, 7:30 AM EST - 1 year ago

Elevation Oncology to Present at the Piper Sandler 35th Annual Healthcare Conference

Nov 2, 2023, 7:30 AM EDT - 1 year ago

Elevation Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Business Achievements

Sep 5, 2023, 7:30 AM EDT - 1 year ago

Elevation Oncology to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 16, 2023, 7:30 AM EDT - 1 year ago

Elevation Oncology Announces First Patient Dosed in the Phase 1 Clinical Trial Evaluating EO-3021

Aug 3, 2023, 7:30 AM EDT - 1 year ago

Elevation Oncology Reports Second Quarter 2023 Financial Results and Highlights Recent Business Achievements

Jul 13, 2023, 8:00 AM EDT - 1 year ago

Elevation Oncology Appoints Joseph Ferra as Chief Executive Officer and Promotes Tammy Furlong to Chief Financial Officer

Jun 8, 2023, 10:41 PM EDT - 2 years ago

Elevation Oncology Announces Pricing of $50 Million Public Offering

Jun 8, 2023, 4:01 PM EDT - 2 years ago

Elevation Oncology Announces Launch of Proposed Public Offering

Jun 3, 2023, 9:00 AM EDT - 2 years ago

Elevation Oncology Highlights First-in-Human Phase 1 SYSA1801 (EO-3021) Clinical Data to be Presented by Partner CSPC Pharmaceutical Group Limited at ASCO 2023

May 15, 2023, 7:30 AM EDT - 2 years ago

Elevation Oncology Reports First Quarter 2023 Financial Results and Highlights Recent Business Achievements

Apr 26, 2023, 4:05 PM EDT - 2 years ago

Elevation Oncology Highlights Clinical Data for SYSA1801 (EO-3021) to be Presented by Partner CSPC Pharmaceutical Group Limited at ASCO 2023

Apr 17, 2023, 10:15 AM EDT - 2 years ago

Elevation Oncology Presents EO-3021 Preclinical Proof-of-Concept Data and Highlights a Clinical Case Study in Claudin 18.2-Expressing Cancers at AACR 2023

Mar 14, 2023, 4:30 PM EDT - 2 years ago

Elevation Oncology to Present at the American Association of Cancer Research (AACR) Annual Meeting 2023

Mar 9, 2023, 7:30 AM EST - 2 years ago

Elevation Oncology Reports Fourth Quarter and Full Year 2022 Financial Results

Mar 1, 2023, 7:00 AM EST - 2 years ago

Elevation Oncology to Participate at Upcoming Investor Conferences

Feb 8, 2023, 7:00 AM EST - 2 years ago

Elevation Oncology to Present at the SVB Securities Global Biopharma Conference

Jan 9, 2023, 7:30 AM EST - 2 years ago

Elevation Oncology to Present at the 41st Annual J.P. Morgan Healthcare Conference